Categories : Endocrine & Metabolic
Product Packaging : 10 / 30 tablets
Product Composition : 30 mg + 500 mg + 15 mg, 60 mg + 500 mg + 15 mg
Send MessageGliclazide SR + Metformin HCl SR + Pioglitazone Tablets represent an advanced triple-drug sustained-release formulation designed for comprehensive management of type 2 diabetes mellitus. This combination integrates three complementary mechanisms: Gliclazide SR enhances pancreatic insulin secretion, Metformin SR reduces hepatic glucose production and improves insulin sensitivity, while Pioglitazone works as an insulin sensitizer acting on peripheral tissues.
The sustained-release technology ensures gradual drug release, maintaining stable plasma levels and improving long-term glycemic control. This formulation is particularly beneficial for patients with poorly controlled diabetes who require multi-drug therapy to achieve optimal metabolic balance.
Genliva Wellness LLP, Himatnagar, India, is a reliable gliclazide metformin pioglitazone tablet manufacturer India pharma and triple combination antidiabetic tablets exporter India, offering WHO-GMP compliant, high-quality formulations tailored for global pharmaceutical supply chains.
Gliclazide SR + Metformin HCl SR + Pioglitazone Tablets are triple-combination antidiabetic medications designed to provide comprehensive blood glucose control in type 2 diabetes mellitus. The sustained-release formulation supports prolonged therapeutic action and improved glycemic management.
These tablets are commonly used for the management of type 2 diabetes mellitus in adults when single or dual therapy is insufficient. They help improve glycemic control along with diet and exercise.
Gliclazide SR + Metformin HCl SR + Pioglitazone Tablets provide multi-targeted glucose control with improved metabolic support and enhanced patient convenience for effective diabetes management.
